Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;35(8):2416-2418.
doi: 10.1038/s41375-021-01173-w. Epub 2021 Feb 15.

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI

Johan Richter  1 , Anna Lübking  2 , Stina Söderlund  3 , Kourosh Lotfi  4 , Berit Markevärn  5 , Anders Själander  6 , Leif Stenke  7 , Stefan Deneberg  8 , Erik Ahlstrand  9 , Kristina Myhr-Eriksson  10 , Panayiotis Panayiotidis  11 , Tobias Gedde-Dahl  12 , Daniela Žáčková  13 , Jiří Mayer  13 , Ulla Olsson-Strömberg  3 , Francois-Xavier Mahon  14 , Susanne Saussele  15 , Henrik Hjorth-Hansen  16 , Perttu Koskenvesa  17
Affiliations

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI

Johan Richter et al. Leukemia. 2021 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

UOS has received honoraria from Ariad. PK has received honoraria from Novartis, Incyte, and Pfizer. DZ served on a speaker’s bureau for Bristol Myers Squibb and Angelini, as a member of Advisory board for Novartis and Incyte, and as a consultant for Angelini. The other authors have no disclosures to make.

References

    1. Dulucq S, Astrugue C, Etienne G, Mahon FX, Benard A. Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years. Br J Haematol. 2020;3:452–68. doi: 10.1111/bjh.16408. - DOI - PubMed
    1. Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;6:747–57. doi: 10.1016/S1470-2045(18)30192-X. - DOI - PubMed
    1. Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;5:424–30. doi: 10.1200/JCO.2012.48.5797. - DOI - PubMed
    1. Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;3:298–305. doi: 10.1200/JCO.2016.68.2914. - DOI - PubMed
    1. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35. doi: 10.1016/S1470-2045(10)70233-3. - DOI - PubMed

Publication types

MeSH terms

Substances